Last reviewed · How we verify
Intrarosa
At a glance
| Generic name | Intrarosa |
|---|---|
| Also known as | prasterone, Dehydroepiandrosterone, DHEA |
| Sponsor | Center for Vulvovaginal Disorders |
| Target | Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Dyspareunia
- Systemic lupus erythematosus
Common side effects
- Vaginal discharge
- Abnormal Pap smear
Serious adverse events
- Low-grade squamous intraepithelial lesion (LSIL)
- Atypical cells of undetermined significance (ASCUS)
Key clinical trials
- Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial (PHASE2)
- Allostatic Load Assessment Using Hair Cortisol and Dehydroepiandrosterone Sulfate Concentration in Patients Affected by Periodontal Disease (NA)
- Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) (PHASE2)
- Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer (PHASE2)
- Neurobiological Mechanisms of Stress in Youth With Chronic Widespread Pain (NA)
- Peri-Implant Sulcus Fluid Stress Markers in Health and Disease
- Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization (PHASE2, PHASE3)
- Effects of DHEA in Pulmonary Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intrarosa CI brief — competitive landscape report
- Intrarosa updates RSS · CI watch RSS
- Center for Vulvovaginal Disorders portfolio CI